
|Videos|August 23, 2017
Dr. Hammers on Next Steps with Immunotherapy in RCC
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).
Advertisement
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).
Data are still needed to determine the response of nivolumab (Opdivo) in certain subsets of patients, states Hammers. If there is a signal of clinical activity, it might be studied in combination with other regimens for this patient population.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
3
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
4
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
5


















































